Zymfentra (Infliximab-dyyb) REal World Cohort STudy
NCT07237516
This study is recruiting at 11 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this observational study is to learn about how effective Zymfentra (IFX=dyyb) is when treating patients with Crohn's disease (CD) and ulcerative colitis (UC) Does Zymfentra lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed Zymfentra (IFX-dyyb as part of their regular medical care for CD or UC will answer online survey questions about their bowel habits for 1 year.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Ulcerative Colitis (UC)
- Crohn's Disease (CD)
- Indeterminate Colitis
- Inflammatory Bowel Disease (IBD)
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of North Carolina, Chapel Hill
- Last updated on ClinicalTrials.gov
- August 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Yale University School of Medicine · New Haven, CT
Florida · 2
- University of Miami · Miami, FL
- AdventHealth · Orlando, FL
Iowa · 1
- University of Iowa · Iowa City, IA
Maryland · 1
- Mercy Medical Center · Baltimore, MD
Massachusetts · 1
- Brigham and Women's Hospital · Boston, MA
New York · 1
- New York University · New York, NY
North Carolina · 3
- University of North Carolina · Chapel Hill, NC
- Atrium Health Center for Gastroenterology and Surgery · Charlotte, NC
- Wake Forest School of Medicine · Winston-Salem, NC
Ohio · 1
- University of Cincinnati · Cincinnati, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.